Ajanta Pharma Limited · NSE:AJANTPHARM
Ajanta Pharma — Q1 FY2019 Earnings Presentation
28 slides from Ajanta Pharma's earnings presentation, Jul 31, 2018
Slide 1: Investor Presentation Q1 FY 2019
Investor Presentation Q1 FY 2019 31st July, 2018
Slide 2: Content
Content 1. India Business 2. Global Business 3. Infrastructure 4. Financial Highlights 5. Recognition 31st July 2018 2 of 28
Slide 3: India Business
India Business 31st July 2018 3 of 28
Slide 4: India Branded Generics
India Branded Generics 15 3000+ 1st Divisions MRs 270+ to Market for 4 Segments Building Efficiency Product Basket Products Continue to focus on 4 Therapeutic Segments with sizeable chronic portfolio Cardiology Ophthalmology Dermatology Pain Management Growth continues exceeding Maintaining Top 3rd
Slide 5: IPM - Ranking
IPM - Ranking Mar 2005 Jun 2017 Jun 2018 Ophthal 28 3 3 Derma 98 13 15 Cardio 38 19 16 Pain NA 45 43 Ajanta 88 33 32 Source: IMS MAT 31st July 2018 5 of 28
Slide 6: India Sales
India Sales Sales Q1 FY19 ` 178 cr. Up 24% Rs. 143 cr. in Q1 FY18 IMS MAT IMS MAT June 2018 June 2017 Pain Pain 6% 6% Ophthalmology Cardiology Ophthalmology 29% 41% 30% Cardiology 40% Dermatology Dermatology 25% 23% 31st July 2018 6 of 28
Slide 7: Industry Growth
Industry Growth 26% 23% 16% 14% 12% 9% 8% 7% 6% 6% Mar-2015 Mar-2016 Mar-2017 Mar-2018 Jun-2018 IPM = Indian Pharmaceutical Market Source: IMS MAT June 2018 IPM Ajanta Pharma 31st July 2018 7 of 28
Slide 8: Segment Growth
Segment Growth 14% 12% 11% 10% 8% 7% 7% 7% 5% Pharma Market Cardiology Ophthalmology Pain Mgt. Dermatology -1% IPM Ajanta Pharma IPM = Indian Pharmaceutical Market Source: IMS MAT June 2018 31st July 2018 8 of 28
Slide 9: Global Business
Global Business 31st July 2018 9 of 28
Slide 10: Global Presence
Global Presence CIS USA 4 WA SEA 3 3 AFRICA 19 INDIA CIS – Commonwealth of Independent States SEA – South East Asia Figures represent no. of countries we are present USA – United States of America WA – West Asia 31st July 2018 10 of 28
Slide 11: Branded Generic Business in Emerging Markets
Branded Generic Business in Emerging Markets Africa Asia + Product Registration 1,000 + 380 + 4 New Products launched 2 pines 4th Leading Position 17th in Franco in Philippines 31st July 2018 11 of 28
Slide 12: USA
USA 20 4 16 Final Approvals Tentative Approvals Under Approvals 1 in Q1 FY 2019 2 in Q1 FY 2019 1 in Q1 FY 2019 18 ~10-12 Products Filing Target on shelf in FY 2019 31st July 2018 12 of 28
Slide 13: Export Sales – Q1 (Consolidated)
Export Sales – Q1 (Consolidated) Regional Break-up (Rs. cr.) Total Exports (Rs. cr.) Q1 FY 2018 Q1 FY 2019 35% 129 1% 321 324 9% (44%) 96 97 78 13% 71 61 54 54 (10%) 2 2 Q1 FY 2018 Q1 FY 2019 Africa Branded Asia USA Africa Others Institution Rs. cr. Q1 FY 2018 Q1 FY 2019 Gth Africa Branded Generic 7
Slide 14: Total Consolidated Sales
Total Consolidated Sales Revenue Break-up (Rs. cr.) Rs. cr. Q1 8% Q1 Q1 Gth 1% 502 FY 2018 FY 2019 464 India 143 178 24% 321 324 24% Exports 321 324 1% 178 143 Total Revenue 464 502 8% India Exports Total Revenue Q1 FY 2018 Q1 FY 2019 31st July 2018 14 of 28
Slide 15: Infrastructure
Infrastructure 31st July 2018 15 of 28
Slide 16: Enabling Infrastructure
Enabling Infrastructure Formulation Manufacturing 3 facilities in Aurangabad, Maharashtra (1 USFDA & WHO Pre-Q approved) New US FDA approved facility in Dahej (Gujarat) New facility in Guwahati (Assam), Derma section commenced 1 Facility at Mauritius API Manufacturing 1 Facility at Waluj (
Slide 17: R&D Thrust
R&D Thrust Revenue Expenses Q1 FY 2019 - Rs. 41 cr. (8%) (Q1 FY 2018 – Rs. 42 cr. (9%) R&D spend & % of Oper. Income (Excluding Capex) 9% Team of 8% 186 850+ Scientists 6% 153 5% 4% 106 70 50 FY 2014 FY 2015 FY 2016 FY 2017 FY 2018 31st July 2018 17 of 28
Slide 18: Financial Highlights
Financial Highlights 31st July 2018 18 of 28
Slide 19: P&L Synopsis – Q1 FY 2019 (Consolidated)
P&L Synopsis – Q1 FY 2019 (Consolidated) Q1 Q1 % Rs. cr. % % FY 2019 FY 2018 Growth Exports 324 63% 321 68% 1% Domestic 178 35% 143 30% 24% Other Op. Income 9 2% 9 2% 2% Income from Operations 511 473 8% EBITDA 157 31% 127 27% 24% PBT 148 29% 119 25% 25% PAT 106 21% 95 20% 12% Total Comprehensive In
Slide 20: Detailed P&L – Q1 FY 2019 (Consolidated)
Detailed P&L – Q1 FY 2019 (Consolidated) Rs. cr. Q1 FY 2019 Q1 FY 2018 Income from Operations 511 473 Other Income 8 2% 5 1% Total Income 519 478 Materials consumed 84 16% 94 20% Employee Benefit 105 21% 87 18% Finance Cost 0 0% 0 0% Depreciation 17 3% 13 3% Other Expenses 165 32% 165 35% Total expe
Slide 21: Consistent Track Record (Consolidated)
Consistent Track Record (Consolidated) Consolidated Total Income PAT (Rs. cr.) & PAT Margin (%) (Rs. cr.) 19% 21% 24% 25% 22% 2,155 15% CAGR 2,026 19% CAGR 507 469 1,771 416 1,502 1,230 310 234 2014 2015 2016 2017 2018 2014 2015 2016 2017 2018 31st July 2018 21 of 28
Slide 22: Consistent Track Record (Consolidated)
Consistent Track Record (Consolidated) EBITDA Margin Net Margin (%) 35% (%) 24% 25% 21% 22% 34% 34% 19% 31% 31% 2014 2015 2016 2017 2018 2014 2015 2016 2017 2018 RONW ROCE 47% (%) (%) 43% 50% 40% 45% 37% 44% 41% 26% 30% 2014 2015 2016 2017 2018 2014 2015 2016 2017 2018 31st July 2018 22 of 28
Slide 23: Consistent Track Record (Consolidated)
Consistent Track Record (Consolidated) EPS Dividend per share (Rs.) (FV Rs. 2/-) 13 (Rs.) 58 53 47 8 35 6 27 4 - 2014 2015 2016 2017 2018 2014 2015 2016 2017 2018 Dividend Payout Book Value per share (%) (Rs.) 232 25% 19% 178 18% 18% 135 96 67 0% 2014 2015 2016 2017 2018 2014 2015 2016 2017 2018 31s
Slide 24: Consistent Track Record (Consolidated)
Consistent Track Record (Consolidated) Total Debt / Equity Receivable Days (Nos.) 87 (Ratio) 0.22 79 63 65 61 0.09 0.07 0.00 0.00 2014 2015 2016 2017 2018 2014 2015 2016 2017 2018 Inventory Days Payable Days (Nos.) (Nos.) 62 123 99 48 94 43 85 82 40 40 2014 2015 2016 2017 2018 2014 2015 2016 2017 20
Slide 25: Recognition
Recognition 31st July 2018 25 of 28
Slide 26: Recognition
Recognition 31st July 2018 26 of 28
Slide 27: Thank You
For updates and company information please visit our website: www.ajantapharma.com For specific queries, contact: Rajeev Agarwal - 022-66061377 Thank You rajeev.agarwal@ajantapharma.com Abhineet Kumar – 022-66061814 abhineet.kumar@ajantapharma.com Ajanta Pharma Limited Ajanta House, Charkop, Kandivl
Slide 28: Disclaimer
Disclaimer This presentation may include certain ‘forward looking statements’, based on current expectations, forecasts and assumptions within the meaning of applicable laws and regulations. They are subject to risks and uncertainties which could cause actual outcomes and results to differ materiall